No significant difference in serum chemerin concentration was found between patients with prostate cancer and those with benign prostatic hyperplasia, however, differences were identified between cancer patients with different Gleason scores, a progressive measurement of prostate cancer aggressiveness as determined by tumor cell differentiation [72]. The gene discussed is RARRES2; the disease is prostate carcinoma.